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Abstract 
Surgical outcome for patients suffering from cervical myelopathy (CM) is unpredictable with 
varying motor and sensory symptom recovery. Previous in-vivo magnetic resonance 
spectroscopy (MRS) studies of patients surgically treated for CM have demonstrated 
decreased N-acetylaspartate (NAA)/creatine levels in the motor cortex indicating reduced 
neuronal function. The goal of this thesis was to determine whether absolute NAA changes in 
the motor and sensory cortices mirror the pattern of motor and sensory functional change 
observed in patients post surgical treatment. 
MRS data were acquired on a 3.0 Tesla Siemens MRI along with clinical outcome measures 
at baseline, 6-weeks and 6-months post-surgery. The results showed that absolute NAA 
levels declined in both cortices in a similar temporal pattern but opposite in direction to 
clinical motor and sensory functional recovery. Findings suggest that low NAA levels may 
be a trigger for functional recovery although the neural mechanisms involved have not been 
elucidated. 
 
Keywords:  
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Chapter 1  
1 Introduction to Cervical Myelopathy and Magnetic Resonance Spectroscopy 
Chapter 1 of this thesis is divided into three parts. The first part describes the background 
and motivation of this thesis. The second provides a general overview of the anatomy and 
physiology of the brain and spinal column as it relates to cervical myelopathy. Finally, 
the third part of this chapter provides an introduction to proton-magnetic resonance 
spectroscopy (MRS) for the measurement of brain metabolites in-vivo. This method is 
used in Chapter 2 to measure metabolite levels in the brain in people with Cervical 
Myelopathy. 
1.1 Background and Motivation 
As humans age, otherwise healthy, functioning joints begin to slowly deteriorate over 
time. In 1956, Clarke and Robinson presented the first study to characterize the natural 
progression in the degenerative disease known as cervical myelopathy (CM).1 This slow, 
progressive process is the most prevalent form of spinal cord disorder in adults over the 
age of 55.2, 3 CM is a consequence of the narrowing of the spinal canal and eventual 
compression of the spinal cord due to various, naturally occurring, arthritic changes in the 
spinal column.4Depending on the severity of the spinal cord compression, symptoms of 
CM will vary accordingly.  
Symptoms of CM manifest in the form of gait dysfunction, numbness and paresthesia in 
the upper limbs, disturbances in overall hand function, as well as bowel and bladder 
dysfunction.5, 6 Surgical intervention to alleviate the compression of the spinal cord is the 
most widely accepted form of treatment to improve motor and sensory deficits.1, 3, 6-9 
Unfortunately, studies investigating the efficacy of surgery report high variability with 
symptom improvement in only one third of patients, 40% remaining neurologically 
stable, and the remaining 25% of patients continuing to worsen with the passage of 
time.1,8 
Numerous studies have examined the epidemiology of the disease, yet little is understood 
about the exact mechanism of progression and which patients will truly benefit from 
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surgery.4, 10-12 Moreover, the accepted standard of care that suggests that CM requires 
operative intervention, regardless of disease severity,7, 13 is beginning to lose support.2, 14 
It seems that there are two main gaps in the literature.  
The first gap in the literature is the lack of studies in the clinical setting demonstrating the 
tendency of patients with CM to have an earlier recovery of the motor deficits following 
surgery when compared to sensory dysfunction. A widely accepted clinical outcome 
measure used to assess motor and sensory function in patients with CM is the modified 
Japanese Orthopaedic Association questionnaire (mJOA) (Appendix 1-2).15 The mJOA 
includes two questions assessing motor dysfunction in the upper and lower limbs and two 
questions assessing sensory dysfunction in the same fashion. The first two questions 
report a sub score out of 12 points (Q1 out of 5 and Q2 out 7) where the latter two report 
a sub score out of 6 (Q3 out of 3 and Q4 out of 3) for a maximum global score of 18 
points indicating no dysfunction. 
Multiple studies have demonstrated a significant improvement in global mJOA scores 
following decompressive surgery.16-20 A recent non-controlled observational study 
published by Moussellard et al17 assessing sixty seven patients with CM demonstrated 
that at first follow-up, as well as subsequent time points, a significant improvement was 
reported when compared to baseline. Upon further analysis of the data, an important 
detail was observed when interpreting the evolution of mJOA scores over time. Global 
mJOA scores could be divided into two intervals, an early stage with significant 
improvement (p<0.01) between the date of surgery and first follow up (one month post-
surgery), and a second stage with a slight, but significant decrease (p<0.01) between 
initial follow up and final follow up (24 months post-surgery). It is also important to note 
that global mJOA scores in this study remained relatively stable during the second stage 
of recovery until final follow up where the decrease was observed. Although still 
subjectively improved when compared to baseline, patients reported a worsening of 
symptoms as compared to initial follow up. These results leave a few questions 
unanswered. Which symptoms improved, which symptoms continued to worsen, and how 
did these symptoms change between subsequent follow ups? The authors did not report 
the evolution of subgroup scores over time for all time points. Global mJOA scores alone 
3 
 
can be misleading due to the uneven weight placed on each subgroup where the 
combined total value of the sensory symptom questions equals less than one motor 
question alone. Results reported by Moussellard et al17 are difficult to interpret given that 
no information is provided on how each symptom evolved at each time point.  
Al-Tamimi and colleagues published a study20 in 2013 evaluating 204 patients surgically 
treated for CM. Sixty five of those patients were followed for a series of four visits at 
three, 12, 24 and 60 months post-treatment. Each patient was asked to complete a series 
of outcome questionnaires including a visual analogue scale (VAS) for two sensory 
symptoms of arm paresthesia as well as hand paresthesia. Significant improvements 
(p<0.05) were reported in arm paresthesia between baseline and three months and 
between 24 months and 60 months. Similarly, VAS scores in hand paresthesia also 
demonstrated significant improvements (p<0.05) between baseline and three months, 12 
months and 24 months, as well as 24 months and 60 months post-treatment. These results 
contrast those of Moussellard et al17 reporting that symptom recovery is very rapid within 
the first month following surgery but stabilizes afterwards as described by global mJOA 
scores; a score heavily weighted in favour of motor function assessment. Both studies 
present important results with respect to the time course of recovery in patients with CM 
that highlight how rapidly motor function gains can be observed and the delayed response 
in sensory symptoms. 
A second gap in the literature is the lack of studies with consistent follow up intervals 
across patients beginning with an early time point immediately after treatment along with 
continued longitudinal follow-up. A characteristic, post-treatment model based on 
functional and clinical outcome measures outlining the behaviour of CM at both early 
and long term follow up to determine efficacy of treatment has not been established. As 
mentioned above, one exceptional study by Moussellard et al17 evaluated neurological 
recovery in CM patients at one month, six, 12, 18, and 24 months post-surgical treatment. 
This study was the first to establish the relevance of early neurological recovery 
following surgical decompression in patients with CM demonstrating a rapid 
improvement at one month with subsequent stabilization in later time points - a finding 
that would have otherwise been lost had the authors neglected an early follow up. 
4 
 
However, one limitation of this study was that a control group was not provided to 
compare conservative treatment in patients suffering from the same disease. Kadanka et 
al14 reported a three year follow-up study evaluating 68 patients with CM to compare the 
efficacy of surgery to conservative treatment in CM patients. Patients were randomized 
into two groups and evaluated at baseline, six months, one, two and three years post-
treatment. The first group was treated conservatively (non-surgically) and the second 
with surgical intervention. Conservative treatment included immobilization of the neck 
using a soft collar, the use of anti-inflammatory medications, intermittent bed rest for 
patients with pain, and avoiding physically overloading activities, getting too cold, 
manipulation therapies as well as prolonged flexion of the neck. Interestingly, the results 
demonstrated that on average, surgical intervention was not superior to conservative 
treatment.  
Despite this growing scepticism, recent reports21, 22 suggest that the above mentioned 
study14 advocating for non-operative treatment demonstrates insufficient evidence to 
support the belief that non-operative treatment has a role in the management of CM. In a 
consensus statement, Fehlings et al23 further validate this claim by citing a recent multi-
centre study completed by their group that included 278 patients from twelve different 
centres throughout North America.22 Findings from this study demonstrate that on 
average, operative intervention can offer improvements in both function and quality of 
life at twelve months post-surgery when compared to baseline. Although both studies are 
relevant in comparing outcome of surgery, it is important to note that the time points 
described by each study are starkly different. Kadanka et al14 describe results from a 
three-year follow-up while Fehlings et al22 describe results from a twelve month follow-
up. Another important feature is that the study by Fehlings et al22 did not include a 
control group in its methodology. A similar group of patients with non-operative 
treatment was not assessed with the justification that non-operative treatment was both 
unethical and impractical.22 
Given the wide variability of surgical outcome,14, 24, 25 uncovering mutually exclusive 
features between patients who improved following surgery compared to those who did 
not would aid in tailoring treatment for patients with CM. Numerous studies have been 
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published finding no link between demographic information, symptomatology, and spinal 
column abnormalities of those affected by CM with surgical outcome.5, 8, 26-29 Previous 
work by our group19, 30 demonstrated changes in the motor cortex of the brain in-vivo, a 
region distal to the site of injury at the spinal cord. More specifically, Kowalczyk et al30 
used non-invasive magnetic resonance spectroscopy (MRS) to measure metabolic 
changes in the motor cortex of CM patients compared to control subjects. The results 
showed that the ratio of N-acetylaspartate (NAA) to creatine (Cr) was lower in CM 
patients indicating impaired mitochondrial function distal to the site of injury. In a 
follow-up study examining motor cortex metabolite levels in CM patients six months 
following spinal decompression surgery, Kowalczyk et al31 showed the NAA/Cr level 
remained low in spite of recovery in motor symptom function. This finding suggests 
continued impairment of mitochondrial function. 
The purpose of this thesis is to expand on this finding while addressing two gaps in the 
literature. To our best knowledge, there has been no study of CM patients that has 
addressed the role of the sensory cortex in the progression and recovery of function 
following surgery, or examined how sensory symptom recovery differs from motor 
symptom recovery over time. Because patients experience both motor and sensory 
functional deficits, we expect to see changes in the sensory cortex similar to those 
observed in the motor cortex in previous studies.31 The second gap in the literature is the 
lack of studies reporting at early follow-up times. The only other study to evaluate early 
neurological recovery was Moussellard et al.17 Neurological status in early follow-up 
demonstrated rapid gains in function with typical plateau while paresthesia and numbness 
persisted into later time points.17 Validating these studies and demonstrating metabolic 
and clinical profiles of patients in terms of sensory and motor deficit will aid in tailoring 
individualized patient care and post-surgical rehabilitation. 
1.2 Anatomy and Physiology of the Cervical Spine 
1.2.1 The Cervical Vertebrae 
The cervical spine consists of the smallest and lightest bones of the vertebral column and 
is susceptible to degeneration causing abnormalities in shape as well as size. The most 
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superior portion of the vertebral column forms the neck and can be categorized into three 
subgroups defined by morphological and functional characteristics; the atlas, the axis, 
and the sub axial spinal column. The atlas (C1) is the most superior vertebra and cradles 
the base of the skull. The second vertebra known as the axis (C2), serves as a pivot for C1 
to aid in rotation and support of the head.32 The final section of the neck is the cervical 
column that consists of cervical vertebrae three through seven. The cervical vertebrae 
include the body, the vertebral arch (pedicles, laminae), facets and spinous processes.  
The vertebral arch arises posteriorly from the vertebral body and consists of the pedicles, 
facets and laminae. The pedicles, directed in the posterior-lateral direction, straddle the 
vertebral foramen and function to protect the spinal cord. On either side of the vertebral 
foramen are the laminae that converge posteriorly to form the spinous process, the most 
posterior point of the vertebra. Bony spurs may result from degeneration of the vertebral 
arch as well as vertebral body. These spurs can impinge into the spinal canal or neural 
foramen, causing compression of the spinal cord or nerve roots, respectively. The 
laminae are also the site of attachment of the ligamenta flava that assist in the 
maintenance of upright posture and overall stability of the neck. Degeneration of the 
ligamentum flavum results in hypertrophy of this ligament, with resulting spinal cord 
compression. A combination of degenerative changes, anteriorly and posteriorly, result in 
narrowing of the spinal canal and spinal cord compression (Figure 1-1). 
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Figure 1-1: Sagittal T2-weighted MR image showing a cervical spine compression and 
signal change in the spinal cord the between cervical vertebrae 3 (C3) and cervical 
vertebrae 4 (C4). 
1.2.2 Intervertebral Discs 
In between all vertebral bodies lies an intervertebral disc. Each disc secures adjacent 
vertebrae in place to form a joint to allow for flexibility and an even distribution of load 
across the disc.33 An intervertebral disc includes three major components. The first 
component, the outer annulus fibrosus, consists of densely packed concentric rings of 
collagen fibril lamellae and fibrocartilage.33 The fibres of the outer layer are arranged 
obliquely where, in each successive ring, the corresponding fibres are perpendicular to its 
adjacent ring, giving the intervertebral disc tensile strength and elasticity.34 The second 
component of the intervertebral disc is the nucleus pulposus that is found on the inside of 
the disc surrounded by the annulus fibrosus. This layer is gelatinous in nature and is 
mainly composed of chondrocyte-like cells, proteins fibres such as collagen, and 
proteoglycan aggrecans that combine to form a three-dimensional matrix in the form of a 
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gel lattice where the loose fibres are suspended in a mucoprotein gel.34 The third and final 
component of the intervertebral disc is the cartilaginous plate.  
Over time, cartilaginous fibres begin to lose elasticity. In order for a disc to function 
properly, it must have high water content. A well hydrated disc is both strong and pliable 
to be able to withstand axial load. As the disc dehydrates, it loses ability to support the 
axial load causing a weight bearing shift from the nucleus pulposus, outward, onto the 
annulus fibrosus, outer vertebral body, and facets. Ultimately, increased forces on the 
annulus lead to fissuring, tearing, disc bulging and herniations. 
1.2.3 The Spinal Cord 
The spinal cord is the main route for all information linking the brain and the peripheral 
nervous system and is an integral part of the central nervous system. The most important 
roles the spinal cord has in the body are autonomic, motor function control and sensation 
perception. This complicated network of bundled neurons contains different tracts and 
pathways. More specifically, the ascending and descending tracts of the nervous system 
form the sensory and motor pathways of communication to and from the brain. 
1.2.4 Principal Descending Tracts 
Within the spinal cord there are two types of descending motor tracts: the corticospinal 
tracts and the subconscious tracts. The corticospinal tracts consist of three pairs of 
descending tracts. The first pair, the corticobulbar tracts, is responsible for conscious 
control over the face, jaw and eye muscles. The remaining two and most relevant to 
cervical myelopathy, the lateral and anterior corticospinal tracts, are both responsible for 
the conscious control over skeletal muscles. These two pathways are known as the 
pyramidal tracts (Figure 1-2). When damaged, atrophy and muscle weakness is observed. 
The second of the two types of descending tracts, are the subconscious motor pathways. 
They consist of four different tracts that are responsible for unconscious motor control: 
the tectospinal tracts, reticulospinal tracts, vestibulospinal tracts and rubrospinal tracts. 
The tectospinal tracts are responsible for the coordination of information and movement 
of the head and neck, while the reticulospinal tracts are responsible for the coordination 
of the eyes and respiratory muscles. Similar to the tectospinal tracts, the vestibulospinal 
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tracts also monitor the position of the head, but more importantly, alter neck muscle 
contraction, muscle tone as well as the limbs for the maintenance of posture and balance. 
Deterioration of this spinal tract results in ataxia, the loss of full control of muscle 
movements with clinical manifestations in loss of balance and posture. Finally, the 
rubrospinal tract relays information to the flexor and extensor muscles. This tract is 
thought to be smaller and less densely packed with axons often cited as a relatively minor 
pathway in humans.35, 36 
 
Figure 1-2: Example of the pyramidal tracts of the principal descending (motor) 
pathways from the brain to the spinal cord. 
 
1.2.5 Principal Ascending Tracts 
Sensory neurons from the ascending tracts deliver information from the spinal cord to the 
brain. The posterior column tract, the spinothalamic tract, and the spinocerebellar tract 
are the three major sensory tracts of the ascending pathway. The posterior column tracts 
consist of two components, the fasciculus gracilis that transmits information from areas 
below thoracic vertebra six (T6), and the fasciculus cuneatus that transmits information 
from areas above T6 that travel to the brain via the posterior section of the spinal cord, 
medially to the posterior gray horn. The fasciculus cuneatus is more relevant to this work 
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as it includes information being transmitted via the cervical spinal cord. Proprioception, 
pressure, fine touch and vibration sensation information are transmitted to the brain via 
these tracts. The spinothalamic tracts are responsible for transmitting pain, temperature, 
crude touch as well as pressure sensations first to the thalamus via the spinal cord and 
finally to the sensory cortex with decussation in the medulla (Figure 1-3). 
 
Figure 1-3: Example of the posterior pathways of the principal ascending (sensory) 
pathways to the brain via the spinal cord from the right side of the body. 
 
1.2.6 Motor and Sensory Cortex 
The motor cortex, located in the most posterior part of the frontal lobe, is one of the most 
important areas of the brain in controlling voluntary movements. This area of the brain 
receives information from different parts of the brain and spinal cord to aid in 
communication via descending tracts for voluntary movements. The sensory cortex, 
located directly posterior to the motor cortex, is the main area of the brain responsible for 
tactile sensation perception.  
Researchers have reliably depicted how the body is cortically represented along the motor 
and sensory cortex.37 The cortical homunculus, a somatic representation of the body in 
the cortex, was first described by Penfield and Boldrey37 in 1937 by electrically 
11 
 
stimulating the brain and observing its affects. More recently, studies38, 39 have been able 
to reproduce findings by Penfield and Boldrey37 with non-invasive and more accurate 
techniques. More specifically, Yousry et al39 identified a new landmark specific to the 
hand region of the motor cortex using functional MRI. This result was of particular 
interest to CM researchers, as some of the main complaints of patients suffering from the 
disease relate to weakness, numbness, paresthesia and loss of dexterity in one or both 
hands.4, 10-12, 40 Yousry et al39 localized the hand region of the brain to a shape resembling 
a “knob” visible in the sagittal view of the motor cortex in the precentral gyrus indicated 
by the red circle in Figure 1-4. The same landmark can also be observed in the axial view 
of the brain in the form of an omega. The hand region of the sensory cortex is located 
directly posterior to the hand region of the motor cortex. Landmarks in the axial and 
sagittal view used to locate the hand area of the motor cortex are also used to locate the 
hand area of the sensory cortex. 
 
Figure 1-4: Sagittal T1-weighted MRI outlining the characteristic “knob” region of motor 
cortex controlling hand function. 
Previous studies have demonstrated cortical plasticity41-44 as well as cortical atrophy45, 46 
in patients with spinal cord injury. Results from these studies demonstrated that patients 
who suffered from damage to the spinal cord were not only affected by motor, sensory 
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and limb impairment below the site of injury, but measurable changes upstream from the 
injury. 
1.3 Magnetic Resonance Spectroscopy 
Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that allows 
the measurement of low concentration mobile metabolites in the brain.47 It is a valuable 
clinical and research-applicable tool47-49 that is used to study a variety of different 
pathologies including epilepsy,50 traumatic brain injury,51 amyotrophic lateral sclerosis 
(ALS),52 and cancer.53 Measurements are made from predefined volumes of tissue called 
voxels.54 
 
Figure 1-5: Three plane MR images with a voxel outlined in yellow. Saturation bands 
are placed around the voxel to null signal from outside the volume of interest. 
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MRS spectra are typically acquired from a small, localized volume of interest in the 
brain. Operationally on the scanner, this voxel is placed over the area of interest and 
positioned using three frames of reference; sagittal, axial, and coronal images. Saturation 
bands are placed near the boundaries of the voxel to exclude signal from the surrounding 
tissue. Localization of signal from a region of interest is achieved using gradients that 
selectively excite three orthogonal planes. Only signal from the intersection of all three 
excited planes is properly refocused and forms the signal we measure from the selected 
region of interest. The pulse sequence used to acquire data in this thesis is called “Point-
Resolved Spectroscopy” (PRESS). The PRESS pulse sequence is composed of three slice 
selective radiofrequency pulses – a 90°, followed by two 180° pulses. These 
radiofrequency pulses select slabs in orthogonal directions and the intersection of all 
three slabs define the voxel.60 
 
Since approximately 80% of the brain is occupied by water55 this signal may conceal 
smaller metabolite peaks and therefore must be suppressed prior to measurement of the 
low concentration metabolites. The water signal is suppressed at the time of the MRS 
data acquisition.57 Water suppression involves a chemical shift selective (CHESS) 
element.56 CHESS employs a 90° Gaussian shaped radiofrequency pulse that allows for 
only a specific range of frequencies in the sample to be selected with a narrow bandwidth 
followed by a dephasing gradient pulse.56 Optimization of this technique is achieved by 
repeating this technique with varying radio frequency pulse amplitudes. Water 
suppression techniques reduce the water signal significantly but do not eliminate it. To 
remove the water completely from the spectrum before quantifying metabolite levels, we 
can fit the water peak using a Lanczos Singular Value Decomposition57 and subtract its 
contribution from the spectrum. 
 
Macromolecules from within the brain and lipid signals from outside the brain in the 
dermis and epidermis can also contaminate the in-vivo spectrum and may interfere and 
overlap with metabolite peaks.57 These macromolecule and lipid signal should also be 
removed to clean the data prior to metabolite concentration quantification.57 Unwanted 
14 
 
signals from lipids are visible between 0 and 1 ppm in the spectrum. Unwanted lipid 
signals are first minimized during acquisition by careful placement of the MRS voxel, 
being diligent to exclude as much lipid containing substances, such as skin, as possible. A 
second technique to suppress lipid signals is the placement of selective saturation bands 
around the voxel in each orthogonal direction to null the lipid signal (Figure 1-5). Despite 
these techniques, lipid signals are sometimes still detected during data acquisition. 
Remaining signal can be subtracted using a technique such as the Lanczos Singular Value 
Decomposition fitting of the spectrum and subsequent removal of peaks within a 
predefined frequency range.57 
Eddy currents are induced by changing magnetic fields. In the case of MRS, successive 
rapid switching of gradient magnetic fields creates eddy currents that introduce signal 
artefacts in the MRS spectrum. Eddy current artefacts are corrected by using the 
unsuppressed water signal as a reference. An eddy current correction (ECC) is used, 
which applies a point by point phase correction of the time domain signal of the spectra 
acquired.58 Another technique, quantification by conversion to Lorentzian type 
deconvolution59 (QUALITY) can be applied by dividing the spectra by the unsuppressed 
water signal. This method also removes eddy current distortions. A combined 
QUALITY/ECC approach was used in the current study to optimize results. 
1.3.1 Characteristics of a 1H MR Spectrum 
An in-vivo spectrum contains multiple characteristic frequencies that correspond to 
different metabolites. Magnetic resonance spectra are characterized by one or more peaks 
with each peak having an associated resonant frequency, line width, phase, and area.61 
Each metabolite molecule contains one or more specific hydrogen chemical environments 
that lead to unique resonant frequencies for the hydrogen nuclei in the molecule. In the 
case of NAA, the dominant peak in the spectrum is produced by the methyl protons 
(CH3¯) shown in Figure 1-6. 
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Figure 1-6: Chemical structure of N-acetylaspartate with methyl singlet peak  
(―CH3¯) circled in red. 
The area under a particular peak is directly proportional to the concentration of the 
corresponding metabolite that it represents as shown in Figure 1-7. NAA generates the 
largest metabolite peak (largest amplitude) in the MRS spectrum and its CH3 methyl 
group is located at 2.02 ppm. 
 
Figure 1-7: An example 1H-MRS in-vivo spectrum of NAA signal localized to the area 
of the motor cortex that controls the hand function located in the precentral gyrus of the 
brain. 
1.3.2 Measurement of Metabolite Concentration 
Spectra are analyzed by fitting linear combinations of known metabolite line shapes to 
the in-vivo spectrum. Prior knowledge of in-vitro metabolite spectra are derived from 
spectra of metabolites in aqueous solution measured at 37 degrees Celsius and pH 7 to 
replicate the conditions that would be experienced in-vivo.62 
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In this thesis there were six metabolites that were modeled and measured in the brain by 
long echo-time proton spectroscopy:61 N-acetylaspartate (NAA), creatine (Cr), choline 
(Cho), glutamine (Gln), glutamate (Glu), and myo-inositol (mI).  
NAA is one of the most abundant amino acids found in the human brain with an average 
concentration of 9.2 mmol/g.63-65 It is considered a marker of neural health and integrity47 
and has been shown to be distributed throughout the neuron and axon.66 NAA is the focus 
of the work described in this thesis. Studies have related NAA to brain metabolism by 
investigating different brain pathologies. By characterizing the areas of the brain that 
demonstrate consistent NAA abnormalities and correlate with disease progression MRS 
provides non-invasive metabolic information that no other tool is currently capable of 
matching.47 For example, NAA has been found to be decreased in many degenerative, 
neurological diseases including forms of dementia,67 multiple sclerosis,68 epilepsy,69 post 
traumatic stress disorder,70 and stroke.71 Patients with Canavan’s disease72 as well as 
children with sickle cell disease73 have been shown to have increased NAA in the brain. 
Although the exact function of NAA has still not been established, synthesis of NAA is 
known to be in the mitochondria of the neuron.74 Dautry and colleagues75 demonstrated 
the involvement of NAA in brain metabolism by treating rats and primates with a 
mitochondrial toxin that significantly reduced the amount of NAA in the brain. Ciccarelli 
et al76 also found that as mitochondrial activity decreased, NAA levels also decreased 
demonstrating an association. In 2005, Madhavarao and colleagues77 suggested a model 
that linked NAA with the production of energy and NAA’s path into cytosol. 
Shown in Figure 1-8, L-aspartate N-acetyltransferase catalyzes the synthesis of NAA 
using acetyl-Co-enzyme A (Ac-CoA) and L-aspartate (Asp). NAA then cycles from the 
neuronal mitochondria through extracellular space into the oligodendrocyte where it is 
hydrolyzed to Asp and acetate with the release of water by available aspartoacylase that 
the neuron otherwise lacks.77 NAA is able to cycle into extracellular space (cytosol) due 
to the high intracellular-extracellular gradient created by the extremely high 
concentration of NAA in the intracellular space compared to that of the extracellular 
space (1000:1).78-80 Studies have also proposed that NAA may be an osmolyte81, 82 where 
the mechanism involved in removing NAA from the neuron involves the movement of 
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water as well (Figure 1-8). This theory suggests that the cycle of NAA synthesis would 
also serve as a molecular water pump83 where water produced by metabolic neuronal 
processes in myelinated neurons would be actively removed as a water-NAA unit against 
a water gradient in the direction of aquaporin-4 (AQP4) water channel proteins.83 AQP4 
water channel proteins are readily available in astrocytes where the water will ultimately 
cross the blood brain barrier (Figure 1-8). To support this theory, data collected in 
humans has shown that for every 1 mol of NAA transport into extracellular space, at least 
121 moles of metabolic water is transported alongside it.63 Thus, NAA may be used as a 
marker of neuronal viability as well as energy metabolism because of its link to 
mitochondrial function. 
 
Figure 1-8 - Proposed synthesis and cycle of NAA. NAA is synthesized with the 
substrates acetyl-co-enzyme A (Ac-CoA) and L-aspartate (Asp) catalyzed by L-aspartate 
N-acetyltransferase (Asp-NAT). Metabolic water (H20) and NAA move out of the neuron 
and NAA becomes hydrolyzed by aspartoacylase (ASPA) with a by-product of acetate 
(Ac) and Asp. H20 moves toward AQP4 eventually crossing the blood brain barrier. Delta 
(Δ) denotes the catalyst of the associated chemical reaction. 
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The metabolites glutamine (Gln) and glutamate (Glu) are abundant in the brain and 
involved in neurotransmission. Glu is an excitatory neurotransmitter involved in memory, 
learning, and cognition84 and has been shown to be decreased in Alzheimer’s disease 
patients.85 Glu is present in most of the brain but concentrated in areas such as the spinal 
cord, outer layers of the cerebral cortex as well as the hippocampus.86 Gln is a precursor 
to Glu found in presynaptic terminals of the neuron. Gln is metabolized into Glu creating 
the most abundant neurotransmitter in the brain.87 Due to their spectral overlap Glu and 
Gln are often evaluated as the sum of Glu+Gln, referred to as Glx. 
In MRS, the measured Cr signal is the combined total concentration of phosphocreatine 
(PCr) and Cr expressed as total Cr.88 Total Cr is used as a marker of energy metabolism 
in astrocytes as well as neurons due to the involvement of phosphocreatine with ATP 
synthesis.88 Specifically, PCr is a readily available substrate for ATP synthesis from ADP 
through the creatine kinase reaction. PCr provides an energy store for fast regeneration of 
ATP. The total Cr signal is assumed to remain relatively constant47 in the normal, healthy 
brain and has therefore been used in many studies as a reference standard to scale 
metabolites. This approach eliminates the need to quantify cerebral spinal fluid (CSF) 
fraction within the voxel to account for changes in tissue partial volume between 
subjects. However the concentration of Cr has been shown to change in pathological 
conditions such as liver diseases.89 Cho is involved in pathways of phospholipid 
synthesis. The vast majority of chemicals in the brain containing choline are non-
soluble.47 Alterations in choline create large increases in MRS visibility of choline-
containing compounds such as phosphatidylcholine, phosphoryl choline, and 
glycerophosphoryl choline.90 MI is considered to be a marker of gliosis and contributes to 
very specific diseases such as dementia.89 In general, mI alone has not been reliably used 
as a diagnostic measure, but one that is used in conjunction with other metabolite 
changes.47 
1.3.3 Thesis Objectives 
The overall goal of this thesis is to determine whether metabolite level changes in the 
motor and sensory cortices mirror the pattern of motor and sensory functional change 
observed in cervical myelopathy patients following surgery. Since there have not been 
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any studies published to date exploring the relationship between metabolic changes in the 
motor and sensory cortices and the temporal recovery of symptoms, this thesis will test 
the following specific hypothesis: that changes in metabolite levels, specifically N-
acetylaspartate, will lag in the sensory cortex compared to the motor cortex, emulating 
the time course of functional recovery. 
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Chapter 2  
2 Magnetic Resonance Spectroscopy in the Motor and Sensory Cortices 
Following Surgery for Cervical Myelopathy 
2.1 Introduction 
Degenerative changes in the cervical spine are part of the natural ageing process. Subtle 
progression is often asymptomatic in most people over 40 years of age.1 Cervical 
myelopathy (CM) is the most prevalent form of spinal cord dysfunction in adults over 55 
and is characterized by a sequence of changes occurring in the spinal column including 
intervertebral disc degeneration, collapsing of disc space, degenerative narrowing of the 
spinal canal, formation of osteophytes, and hypertrophy of the ligamentum flavum, 
lamina and facets.2-4 As a result, symptoms begin to develop in a gradual but progressive 
step-wise manner.3, 5, 6 
Clinically, CM manifests itself in patients with upper limb sensory loss, loss of dexterity, 
numbness, paresthesia and weakness in upper and lower limbs, loss of proprioception and 
in more severe cases, bowel and bladder incontinence.7-9 Following decompressive 
surgery, patients typically experience motor function improvement at early follow-up.  
For example, strength in upper limbs and gait dysfunction improve both subjectively and 
in objective measures along with improvements in overall balance.10, 11 Gains in motor 
function typically plateau while paresthesia and numbness persist with slow 
improvements in neurological status later in recovery.11 
Previous work completed by our group showed significantly decreased N-acetylaspartate 
(NAA)/creatine (Cr) ratio in the motor cortex of CM patients compared to healthy control 
subjects using proton-magnetic resonance spectroscopy (MRS).12 MRS is a non-invasive 
imaging technique that enables the measurement of high-concentration mobile 
metabolites in a given volume of tissue in the brain.13 Such metabolites include N-
acetylaspartate, choline, creatine, myo-inositol, glutamate (Glu), and glutamine.  
The two primary metabolites of interest in this study are NAA and Glu. NAA is found 
exclusively in neurons as well as neuronal processes and is therefore a marker of 
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neuronal integrity.14, 15 NAA has also been found to be decreased in several other disease 
conditions such as Alzheimer’s disease, bipolar disorder, stroke and schizophrenia.16 
NAA is a free amino acid synthesized in neuronal mitochondria from L-aspartate and 
acetyl-coenzyme A in reactions that are catalyzed by N-acetyltransferase.17-19 It is then 
later transported to the cytosol by translocase and hydrolyzed by the amidohydrolase, N-
acetyl-L-aspartate.20 Physiologically, however, the role of NAA is still unknown. 
Presently, studies have proposed that NAA may be a precursor for the neurotransmitter 
NAAG, a neurotransmitter itself, an osmolyte involved in fluid homeostasis, and may 
incite protein synthesis, among other suggestions.21 Glutamate (Glu) is a major excitatory 
amino acid neurotransmitter that is derived by local synthesis of glucose and can also be 
formed directly from glutamine. Glu, among other amino acid transmitters, is used for 
excitatory synaptic transmission in the brain and is crucial in cellular metabolism. 
Decreased Glu levels have been found in other diseases states such as Schizophrenia, 
amyotrophic lateral sclerosis and Alzheimer’s disease.22 
The goal of this study was to determine whether metabolite level changes in the motor 
and sensory cortices mirrored the pattern of motor and sensory functional change 
observed in patients following surgery. Specifically, we hypothesized that at six weeks 
after surgery, the concentration of NAA would be increased in the motor cortex while 
remaining unchanged in the sensory cortex. We also hypothesized that at six months after 
surgery, NAA would be increased in both the motor and sensory cortices compared to 
baseline values. 
2.2 Methodology 
2.2.1 Patient Population 
Twenty-four patients (20 males, 23 right handed, age range: 34 to 67 years, mean age ± 
standard error of the mean; 52 ± 2 years) with CM including a clinical MRI to support the 
diagnosis and no other neurological impairments or previous surgical treatment in the 
brain or spinal column were recruited and participated in this study. All participants 
provided written informed consent according to the Declaration of Helsinki and this study 
was approved by the University of Western Ontario’s Human Subjects Research Ethics 
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Board. At the time of enrolment, all patients demonstrated progressive symptoms 
manifesting no longer than 24 months. All patients had a baseline MRI scan. 17 patients 
underwent surgical treatment and completed two follow-up MRI exams at six weeks and 
six months post surgery that coincided with early and late clinical follow-up visits. 
Eleven out of seventeen (11/17) patients were treated for focal single-level cervical disc 
herniations, while the remaining six patients were treated for multi-level spondylotic 
disease causing myelopathy. Eight control subjects of similar age were recruited (5 
males, 8 right handed, 48 ± 3 years) with no past clinical history of cervical myelopathy 
or previous surgery in the brain or spinal column. Control subjects also completed three 
MRI scans; one at baseline, then repeated at six weeks and six months.  
All patients completed validated clinical outcome measures including the modified 
Japanese Orthopaedic Association Score (mJOA), and the Neck Disability Index (NDI). 
All patients suffering from CM were also assessed using the American Spinal Injury 
Association Impairment Classification scale (ASIA) by a licensed physician. 
2.2.2 Magnetic Resonance Imaging 
All magnetic resonance imaging (MRI) was performed using a 3.0 Tesla Siemens 
(Erlangen, Germany) Magnetom Tim Trio (N=15) or a 3.0 Tesla Siemens Magnetom 
Prisma Fit (N=2) MRI, using a 32-channel head coil. Each exam (total scan time = 48 
minutes) included the acquisition of sagittal 3D T1-weighted inversion prepared 
(inversion time = 900 ms) rapid gradient echo anatomical images (192 slices, 1mm 
isotropic resolution, repetition time/echo time = 2300/3.42 ms) over the whole brain. 
These images produced high grey matter/white matter/cerebral spinal fluid contrast and 
were used for measurement of tissue partial volume within the spectroscopy voxel.  
A 20mm isotropic voxel was positioned in the precentral gyrus over the area of the motor 
cortex that controls hand function as defined by Yousry et al23 using functional activation 
studies. Anatomical landmarks were also used to place the voxel.  For example, in the 
sagittal view, the hand region of the motor cortex has the characteristic hook or “knob” 
type appearance while in the axial view the cortex appears in the shape of an omega. A 
second spectroscopy voxel was placed in the sensory cortex, directly posterior to the 
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voxel placed in the motor cortex. Three-dimensional images of the position of both 
voxels were saved for each participant to aid in placing the voxel over the same area 
during follow-up visits. Voxels were placed in the motor and sensory cortices in the 
contralateral hemisphere to the side of increased clinical deficit (n = 3 on the right, n=14 
on the left side of the brain) while in data acquired for control subjects, spectra were 
acquired in the motor and sensory cortices on both sides of the brain. Data were not 
acquired on both sides of the brain in patients due to discomfort in the arms and neck as a 
result of cervical myelopathy. Water suppressed spectroscopic data were localized using 
point resolved spectroscopy (PRESS, repetition time/echo time = 2000/135 ms, 192 
averages, voxel size = 8 cm3) and water unsuppressed spectroscopic data were acquired 
from the same voxel (PRESS, repetition time/echo time = 2000/135 ms, 8 averages, 
voxel size = 8 cm3). 
Prior to spectral analysis, residual water signal is removed by subtraction using a 
LSVD.24 Resultant spectra were fitted in the time domain using a Levenberg-Marquardt 
minimization routine incorporating a template of prior knowledge of each acquired 
metabolic lineshapes. In house analysis software (fitMAN), created in our laboratory in 
the IDL (Version 5.4 Research Systems Inc.) programming language, was used to model 
each metabolic peak after derived prior knowledge of in-vitro metabolite models.25 An 
example of the fitting is shown in Figure 2-1 where the top line represents the residual 
difference between the in–vivo spectrum and the fitted spectrum. Each metabolite is 
displayed at the bottom of the figure demonstrating its contribution to the spectrum. 
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Figure 2-1: An example spectrum from 1H MR spectroscopy of the area in the motor 
cortex controlling hand function. Top line above the spectrum is the residual line showing 
the result of fitting superimposed on the spectrum acquired from the data. Each 
metabolite is displayed on the bottom half of the figure demonstrating its contribution to 
the spectrum. 
 
Tissue partial volume analysis was performed using the T1-weighted anatomical images 
for each individual subject to determine the fraction of tissue and CSF within the voxel. 
Metabolite levels were normalized to the total tissue water signal and adjusted to account 
for water and metabolite specific T1 and T2 relaxation.  Relaxation time constants 
obtained from the literature from measurements made at 3 Tesla. Based on previous 
studies that have shown specific metabolite involvement in neurological disorders such as 
CM, the following metabolites were measured and reported: NAA, choline, creatine, 
myo-inositol, Glu and glutamine. 
2.2.3 Statistical Analysis 
Absolute concentrations of metabolites were compared between groups using a two-tailed 
Student’s t-test with alpha error of 0.05. For comparisons at different time points 
(baseline, six weeks and six months) in patients, a two-tailed paired Student’s t-test with 
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an alpha error of 0.5 was also used. Correlations between clinical scores and absolute 
metabolite concentrations were determined by the Pearson Correlation Coefficient (r). 
Statistical analysis does not account for multiple comparisons due to the exploratory 
nature of this study as well as the planned comparisons made during the conception of 
this study. 
2.3 Results 
2.3.1 Clinical Outcome Measures 
Table 2-1 summarizes patient and control demographic information as well as the clinical 
outcome measurements made using the NDI, mJOA, and ASIA neurological 
classification scales. Patients that participated in the study demonstrated a significantly 
decreased NDI (Table 2-1) score (p<0.05) from baseline to six months indicating an 
improvement in neck pain and its effect on daily activities. A significant increase was 
also observed in mJOA scores (Table 2-1) from baseline to six months (p<0.001) and 
from six weeks to six months (p<0.05) indicating improvement in both motor and 
sensory function. A trend toward an increase (p=0.07) was also found in the mJOA when 
comparing baseline to six week scores. Patients also showed a significant increase in the 
ASIA scores (Table 2-1), the only objective clinical measure. The ASIA can be 
subdivided into two categories, a motor section and a sensory section. In the motor 
section, there was a significant improvement between baseline and six weeks (p<0.05) 
and between baseline and six months (p<0.05). In the sensory portion of the ASIA, 
specifically with respect to light touch, there was a significant improvement between 
baseline and six months (p<0.01) and between six weeks and six months (p<0.05). 
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Table 2-1: Demographic and Clinical Data for Patients and Controls 
 Patients Controls p-value 
N 17 8 n / a 
Age 52 ± 2 48 ± 3 0.230 
Sex (male/female) 16 / 1 5 / 3 0.136 
Handedness (right/left) 16 / 1 8 / 0 0.332 
NDI scores    
     Baseline 19.2 ± 2.0 2.3 ± 0.8 <0.0001 
     6 weeks 15.9 ± 1.8 2.5 ± 0.9 <0.0001 
     6 months 12.8 ± 2.1 2.9 ± 1.0 0.0002 
mJOA scores    
Baseline    
          Motor questions 8.3 ± 2.5 12 ± 0 <0.0001 
          Sensory questions 4.2 ± 0.8 6 ± 0 <0.0001 
6 weeks    
          Motor questions 9.4 ± 2.1 12 ± 0 <0.0001 
          Sensory questions 4.5 ± 1.0 6 ± 0 <0.0001 
6 months    
          Motor questions 9.7 ± 1.8 12 ± 0 <0.0001 
          Sensory questions 4.8 ± 0.6 6 ± 0 <0.0001 
ASIA scores Right Left Right Left  
Baseline    	    
          Upper motor 23.5 ± 0.4 24.2 ± 0.4 25 ± 0 25 ± 0	   0.0016 
          Lower motor 23.8 ± 0.4 24.3 ± 0.3 25 ± 0 25 ± 0	   0.0012 
          Light touch 24.5 ± 1.3 25.8 ± 1.2 30 ± 0	   30 ± 0	   0.0007 
          Pin prick 24.5 ± 1.2 25.2 ± 1.3 30 ± 0	   30 ± 0	   0.0005 
6 weeks     
          Upper motor 24.7 ± 0.2 24.8 ± 0.1 25 ± 0 25 ± 0	   0.0460 
          Lower motor 24.6 ± 0.3 24.8 ± 0.1 25 ± 0 25 ± 0	   0.2261 
          Light touch 26.8 ± 1.0 28.2 ± 0.7 30 ± 0	   30 ± 0	   0.0029 
          Pin prick 27.0 ± 1.0 28.5 ± 0.7 30 ± 0	   30 ± 0	   0.0041 
6 months     
          Upper motor 24.7 ± 0.2 24.9 ± 0.1 25 ± 0 25 ± 0	   0.0488 
          Lower motor 24.8 ± 0.1 24.8 ± 0.2 25 ± 0 25 ± 0	   0.1300 
          Light touch 29.3 ± 0.3 28.8 ± 0.5 30 ± 0	   30 ± 0	   0.0100 
          Pin prick 29.0 ± 0.7 28.8 ± 0.5 30 ± 0	   30 ± 0	   0.0304 
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2.3.2 Metabolic Changes in the Motor and Sensory Cortices 
When compared to healthy, age matched control subjects at baseline, patients had 
significantly lower concentration of NAA in both the motor (p<0.01) and sensory 
(p<0.05) cortices (Figure 2-2). At baseline, there were no other significant metabolite 
differences between patients and healthy control subjects. The absolute concentration of 
NAA remained stable in control subjects across all three time points, baseline, six weeks 
and six months in both the motor and sensory cortices. Table 2-2 describes the absolute 
metabolite levels in patients with CM at each time point (baseline, six weeks and six 
months post-surgical treatment) in both the motor and sensory cortices. For all three time 
points, there were no significant differences detected (p>0.05) when comparing the 
absolute concentrations of metabolites between the motor and sensory cortices. However, 
the concentration of NAA changed over time in both the motor and sensory cortices 
(Table 2-2, Figure 2-3). Specifically, NAA showed a significant decrease in the motor 
cortex from baseline to six weeks (p<0.05) and from baseline to six months post-
operatively (p=0.05). Interestingly, a different profile was observed in the sensory cortex 
with NAA showing a significant decrease from baseline to six months (p<0.05) and from 
six weeks to six months (p<0.05) post-operatively. There were no other metabolite 
changes in the motor cortex after surgery. In contrast, in the sensory cortex, there was a 
significant change observed in Glx, the sum of glutamate and glutamine. The change was 
observed between baseline and six months (p<0.05) and between six weeks to six months 
(p<0.01). No other changes were observed in absolute metabolite concentrations in the 
sensory cortex.   
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Figure 2-2: Average absolute concentration of NAA in patients (n=24) and controls 
(n=8) at baseline in both the motor and sensory cortices. The error bars represent the 
standard error of the mean and the asterisks represent significant differences between 
groups (p<0.05).  
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Table 2-2: Absolute Metabolite Concentrations (mM) for Patient Group 
 Motor Cortex Sensory Cortex 
 Baseline 6 Weeks 6 Months Baseline 6 Weeks 6 Months 
NAA 15.7 ± 0.4 14.9 ± 0.6* 14.5 ± 0.5* 15.8 ± 0.7 15.8 ± 0.5 14.6 ± 0.5*† 
Glu 4.4 ± 0.3 3.8 ± 0.3 3.8 ± 0.2 4.8 ± 0.4 4.5 ± 0.4 4.2 ± 0.3 
Gln 1.3 ± 0.2 1.2 ± 0.1 1.1 ± 0.3 1.1 ± 0.2 1.3 ± 0.2 0.9 ± 0.1 
Glx 5.6 ± 0.4 5.1 ± 0.3 4.9 ± 0.2 5.9 ± 0.5 5.8 ± 0.4 5.0 ± 0.3*† 
Cr 8.6 ± 0.4 8.3 ± 0.4 7.9 ± 0.3 8.6 ± 0.3 8.9 ± 0.5 8.3 ± 0.3 
Cho 2.5 ± 0.1 2.5 ± 0.1 2.4 ± 0.1 2.6 ± 0.1 2.8 ± 0.1 2.5 ± 0.1 
mI 2.6 ± 0.3 2.4 ± 0.1 2.3 ± 0.1 2.4 ± 0.4 2.4 ± 0.3 2.2 ± 0.2 
NAA = N-Acetylaspartate; Glu = Glutamate; Glx = Glutamate + Glutamine; Cr = Creatine;  
Cho = Choline; mI = Myo-Inositol 
*Significantly different compared to baseline (p<0.05) 
†Significantly different compared to 6 weeks (p<0.05) 
± represents standard error of the mean	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Figure 2-3: The change in average absolute concentrations of NAA in patients with CM 
following surgery. The error bars represent standard error of the mean and asterisks 
represent significant differences between time points. 
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Examining the change in NAA levels with change in clinical scores, a significant 
correlation was found between the change in the motor portion of the mJOA after six 
months and the corresponding change in the absolute concentration of NAA (r=0.44, 
p=0.040, Figure 2-4). Correlations between Glu and NAA were performed between all 
time points in both the motor and sensory cortices. Significant correlations were found in 
the motor cortex between the change in absolute concentrations of NAA and Glu from 
baseline to six weeks (r=0.750, p=0.0003), baseline to six months (r=0.721, p=0.006), 
and six weeks to six months (r=0.599, p=0.006) (Figure 2-5). Similarly, significant 
correlations were also found in the sensory cortex between the change in absolute 
concentrations of NAA and Glu from baseline to six weeks (r=0.528, p=018), baseline to 
six months (r=0.905, p<0.0001) and six weeks to six months (r=0.631, p=0.006) (Figure 
2-5). No other correlations were found when comparing absolute concentrations with 
clinical outcome measures but a similar pattern was observed in significant changes 
between time points in the motor portion of the ASIA questionnaire and the concentration 
of NAA in the motor cortex (Figure 2-6). Similarly, significant changes between time 
points in the concentration of NAA in the sensory cortex and the sensory portion of the 
ASIA questionnaire when testing light touch (Figure 2-7). 
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Figure 2-4: Correlation between the change in scores on the motor portion of the 
modified Japanese Orthopaedic Association questionnaire and the change in the absolute 
concentration of N-acetylaspartate (NAA) in the motor cortex six months after surgery. A 
linear regression line is shown superimposed on the data. 
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Figure 2-5: Correlations between the change in absolute concentration of N-
acetylaspartate and the change in glutamate between two time points. Plots A and B are 
correlations of the change in concentration between baseline and six weeks post-
operatively, plots C and D between baseline and six months, and E and F between six 
weeks and six months. Plots A, C and E are all concentrations in reference to the motor 
cortex and plots B, D, and F are all concentrations in reference to the sensory cortex. In 
each graph, a linear regression line is shown superimposed on the data. 
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Figure 2-6: The change in average absolute concentrations of NAA and average motor 
ASIA scores in patients with CM following surgery. The error bars represent standard 
error of the mean and asterisks represent significant differences between time points. 
 
Figure 2-7: The change in average absolute concentrations of NAA and average sensory 
(light touch) ASIA scores in patients with CM following surgery. The error bars represent 
standard error of the mean and asterisks represent significant differences between time 
points. 
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2.4 Discussion 
This study is the first to characterize the metabolic profile in the motor and sensory 
cortices in patients with CM at baseline, six weeks and six months post-surgery. Clinical 
outcome measures were also collected at all three time points providing a functional 
context for the metabolite level measurements. Our findings demonstrated a decreased 
absolute concentration of NAA in both the motor and sensory cortices in patients 
compared with healthy control subjects at baseline. After surgery, absolute NAA levels in 
the motor cortex decreased at six weeks and six months compared to baseline, but no 
difference was found when comparing six month levels with six week levels. In the 
sensory cortex, patients demonstrated a decrease in absolute NAA concentrations 
between baseline and six months and between six weeks and six months post-treatment. 
A similar pattern was evident in the absolute concentration of Glx (a sum of glutamine 
and glutamate) where there was a significant decrease between baseline and six months 
as well as six weeks and six months. The mJOA, ASIA, and NDI clinical outcome 
measures all showed a significant improvement across time points. Patients consistently 
improved in motor as well as sensory function in both patient-subjective and physician-
objective measures. We found a significant correlation between the decrease in the 
absolute concentration of NAA in the motor cortex between baseline and six months and 
the improvement in patient scores between over the same time interval measured by the 
ASIA neurological classification scale of motor function.  
A previous study by our group Kowalczyk et al12 found decreased NAA/Cr levels in the 
motor cortex in CM patients compared to controls. Decreases found in this ratio were 
attributed to a decrease in NAA rather than an increase in creatine. The current study 
supports the initial finding and provides further evidence to support the notion that it is 
NAA that is declining. The current study is the first to report absolute metabolite 
concentrations in the cortex to evaluate patients with cervical myelopathy. In addition, 
the current study also indicates that decreased NAA may be more widespread in the brain 
as lower levels were also observed in the sensory cortex at baseline. This decrease 
suggests neuronal damage or axonal loss is present in both cortices. It is unclear whether 
these changes are permanent (suggesting neuronal/axonal loss) or whether reduced NAA 
44 
 
indicates there is a decline in mitochondrial function that is potentially reversible.26 When 
comparing the decreases in the absolute concentration of NAA between the motor and 
sensory cortices, a temporal difference was observed.  
The current study also characterized the changes in NAA at six weeks and six months 
following surgery. The decline in NAA levels observed in the motor cortex at six weeks 
and six months post surgery was consistent with a previous study by our group27 that 
showed decreased NAA/Cr levels six months after surgery. The current study confirms 
that NAA is declining while creatine levels are constant. The significant correlation 
between the decrease in NAA and the improvement in motor function six months 
following surgery (Figure 2-4) indicates that individuals with the greatest improvement 
also had the least decline in NAA levels. A decline in NAA level was also observed in 
the sensory cortex, but only six months after surgery. Therefore the NAA decline in the 
motor cortex preceded that observed in the sensory cortex.   
Although there were no other significant correlations between decreases in metabolites 
and improvement in functional scores, we have seen an interesting pattern in the 
physician-objective ASIA neurological impairment scale that mimics that of NAA in the 
motor and sensory cortices. There was a significant improvement observed between 
baseline scores and six week scores, baseline scores and six month scores, and a lack of 
significant improvement between six weeks and six months. This pattern is identical to 
that of the decrease in the absolute concentration of NAA in the motor cortex (Figure 2-
6). A pattern was also observed between the sensory portion of the ASIA neurological 
impairment scores, specifically the portion testing light touch, and the absolute 
concentration of NAA in the sensory cortex (Figure 2-7). A significant improvement 
between baseline and six months, six weeks and six months, but no significant 
improvement between baseline and six weeks directly emulates the pattern observed in 
metabolic changes in the sensory cortex. Although this pattern was not observed among 
the patient-subjective scores and only demonstrated in physician-objective scores, this 
suggests that patients may not be accurately assessing their own function. The lack of 
symptom specific questions among outcome measures as well as patients not having the 
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ability to compare previous answers before completing the questionnaires may be 
misrepresenting true results.  
The only other metabolic measure to change was the sum of glutamine and glutamate 
(Glx), in the sensory cortex, which was decreased at six months following surgery 
compared to baseline and six weeks post surgery. Changes were not observed in Glu and 
Gln independently likely due to the higher relative error in these measurements.  
Glutamate, the major excitatory neurotransmitter in the nervous system is the main 
contributor to the Glx along with glutamine, a glutamate precursor.28 It is noteworthy that 
there was a significant correlation between changes in NAA levels and changes in Glu 
levels at all time points in both the motor and sensory cortices (Figure 2-5). This 
correlation is commonly observed in the brain and suggests that decreased mitochondrial 
function (NAA) neuronal activation is accompanied by decreased neurotransmitter 
activity (Glx). 
Although this study demonstrates that metabolite level changes can be detected as early 
as six weeks following surgery, future studies are needed to determine whether the 
decreases in absolute NAA levels continue beyond six month after surgery, or whether 
NAA levels eventually normalize.  
2.5 Conclusion 
Levels of NAA are decreased in the motor cortex as early as six weeks after spinal 
decompression surgery in patients with cervical myelopathy and remain decreased at six 
months. NAA levels in the sensory cortex also decrease in the sensory cortex after 
surgery, but not until six months post surgery. This decrease in NAA levels is observed 
despite improvement in patient function over the same interval. 
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Chapter 3  
3 Conclusions, Limitations and Future Work 
3.1 Summary 
Cervical myelopathy (CM) is a common, debilitating disease in adults and little is known 
about how the disease progresses or how the spinal cord and brain recover after 
treatment. Previous studies have demonstrated significant functional and metabolic 
differences in the brain in CM patients compared to healthy control subjects. The overall 
goal of this thesis was to evaluate patients with CM before and after surgery to establish a 
metabolic profile in both the motor and sensory cortices. In particular, our aim was to 
relate motor and sensory function at both early and later time-points following surgery to 
metabolic changes.  This work was motivated by the clinical observation that motor 
function returns prior to sensory function in many patients. 
This study evaluated patients before surgery, at early recovery following surgery (at six 
weeks post-treatment) and also at later follow-up (six months post-treatment). We 
hypothesized that at six weeks after surgery, the concentration of N-acetylaspartate 
(NAA) would be increased in the motor cortex while remaining unchanged in the sensory 
cortex. Our second hypothesis was that at six months after surgery, NAA would be 
increased in both the motor and sensory cortices compared to baseline values.  
Results showed that at baseline, patients had a significantly lower (p<0.05) absolute 
concentration of NAA in both the motor and sensory cortices when compared to control 
subjects suggesting mitochondrial dysfunction of affected neurons.  It is unlikely that 
decreased NAA levels are due to neuronal death as the levels of other metabolites were 
mostly unaffected. The absolute concentration of NAA in control subjects remained 
stable across time points in both the motor or sensory cortices. In the motor cortex, the 
absolute concentration of NAA in patients was significantly decreased between baseline 
and six weeks (p<0.05) and between baseline and six months (p<0.05). There was no 
significant decrease between six weeks and six months. Motor symptom recovery, as 
described by the motor portion of the American Spinal Injury Association (ASIA) 
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impairment classification scale, was significantly better (p<0.05) between baseline and 
six weeks and between baseline and six months (p<0.05). There were also no significant 
changes in function between six weeks and six months.  
In the sensory cortex, the absolute concentration of NAA in patients was significantly 
lower between baseline and six months (p<0.05) and between six weeks and six months 
(p<0.05). With respect to sensory function, as described by the sensory portion (light 
touch) of the ASIA impairment classification scale, patients had significant sensory 
improvement between baseline and six months (p<0.05) and six weeks and six months 
(p<0.05). 
We originally hypothesized that NAA levels would increase after surgery – indicating a 
reversal of metabolic dysfunction.  However, the opposite was observed.  The reason for 
declining NAA levels in conjunction with functional recovery is unclear. One possibility 
is that the decrease in NAA is a trigger for cortical plasticity where the brain recruits 
surrounding areas of the cortex to regain lost function. In group average analyses, 
decreases in the absolute concentration of NAA in the motor cortex mirrored the pattern 
of motor function recovery. Similarly in the sensory cortex, decreases in the absolute 
concentration of NAA mirrored the pattern of sensory symptom recovery. However, no 
correlation was observed between the absolute change in NAA and functional recovery 
when examining individual patients. The reason why the observed decline in NAA levels 
lags in the sensory cortex remains unclear because the cause of the decline in NAA has 
yet to be understood. 
To the best of our knowledge, this study is the first to characterize metabolic changes in 
the motor and sensory cortices following surgery in patients with cervical myelopathy. 
The results will aid clinicians in counseling patients following surgery to focus early 
rehabilitation on regaining motor symptom loss such as strength of the arms and legs 
while delaying sensory symptom rehabilitation to a later time in post-surgical recovery. 
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3.2 Limitations 
One limitation of our study was the heterogeneity of our patient group. Although 
stringent criteria were used to recruit study participants, the symptoms of cervical 
myelopathy in patients ranged in severity. It is unclear how the variability of symptom 
severity affects the absolute concentration of NAA in both the motor and sensory 
cortices.  Another limitation of our study was the reproducibility in the placement of the 
magnetic resonance spectroscopy (MRS) voxel in both the motor and sensory cortices. 
To minimize placement error in follow-up scans, we employed projections of the position 
of the voxel in three orientations from the baseline scan for each patient as a reference.  
However differences in head orientation as well as subject motion between the short time 
that the T2-weighted localizer scans were acquired and the voxel placement and 
spectroscopy acquisition could have lead to small errors in voxel placement. It is also 
unclear what effects, if any, surgical intervention had on the cortex and absolute 
metabolite concentrations.  
3.3 Future work 
 This thesis was the first to report significant differences in absolute metabolite 
concentrations in patients surgically treated for cervical myelopathy and healthy control 
subjects. Further studies are needed to determine whether decreases in the absolute 
concentration of NAA continue beyond the six month time point. Continued studies are 
needed in order to determine whether longitudinally, patients with cervical myelopathy 
continue to experience metabolic changes in the cortex that can be influenced by 
rehabilitation or whether metabolite levels stabilize over time. Studies have shown that at 
three years following surgery, patients who were conservatively treated are functionally 
the same as patients who were treated surgically. Moreover, similar studies evaluating the 
absolute metabolite levels of patients conservatively managed are needed to establish a 
metabolic profile for these patients at baseline, six weeks and six months following the 
introduction of conservative treatment.  
Further studies would also benefit from the use of an animal model. With animal studies, 
histology can be used to identify cellular changes caused by the disease at various time 
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points. Histological data as well as advanced imaging techniques, such as positron 
emission tomography (PET), could give us further insight in to the different processes of 
the mitochondria of the affected neurons of the brain allowing us to determine whether 
NAA is a culprit in the degenerative changes of the disease or a by-product of another 
process we are currently unable to detect.  
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